Premature Ovarian Insufficiency Drug Pipeline — PatSnap Eureka
Premature Ovarian Insufficiency: AMH, FSH Analogs & Ovarian Reserve Therapeutics
POI affects approximately 1–3% of women before age 40, driving accelerating research into AMH-guided diagnostics, oral FSH receptor agonists, platelet-rich plasma, and stem cell regeneration strategies. Explore the full pipeline with PatSnap Eureka.
Key Molecular Targets in Premature Ovarian Insufficiency
POI is defined by accelerated depletion of the primordial follicle pool, elevated basal FSH, and declining serum AMH. Research from institutions including PatSnap's life sciences platform tracks six primary target classes driving the pipeline.
AMH — Anti-Müllerian Hormone
Secreted by granulosa cells of preantral and small antral follicles; functions as a negative regulator of primordial follicle recruitment and an inhibitor of FSH sensitivity in growing follicles. Serum AMH is recognized as the most sensitive quantitative index of the ovarian follicle pool. Therapeutic recombinant AMH exploits its upstream inhibitory action to protect the primordial pool during chemotherapy.
TGF-β superfamily · Dual inhibitory mechanismFSHR — FSH Receptor
Target of both recombinant FSH preparations and novel oral small-molecule allosteric agonists (TOP5668, TOP5300). The Ser680Asn polymorphism in exon 10 of FSHR modulates ovarian resistance to exogenous FSH, explaining variable gonadotropin dose requirements across patients. Genotyping via RFLP is used clinically to predict ovarian response.
Ser680Asn polymorphism · Allosteric agonismTrkB — BDNF Receptor
Identified by Tsinghua University as a novel pharmacological target in POI. BDNF is expressed in granulosa cells; TrkB expression increases in oocytes as they mature. BDNF is downregulated in follicles of POF patients. The agonist antibody Ab4B19 completely reversed follicle reduction and normalized gonadal hormone levels in both aging and cyclophosphamide-induced POF mouse models.
BDNF/TrkB signaling · Preclinical proof-of-conceptPTEN-AKT-FOXO3a Pathway
Well established in primordial follicle dormancy maintenance and identified as a specific druggable target. Single-oocyte gene profiling from the Chinese University of Hong Kong identified curcumin as a modulator of this pathway. Long-term curcumin treatment (100 mg/kg) improved AMH, FSH, and estradiol in aging mice and maintained ovarian reserve indicators.
Primordial follicle dormancy · Curcumin modulatorH19 lncRNA & AMH Regulation
Yale School of Medicine data reveal that H19 lncRNA regulates Amh expression via a novel imprinted gene mechanism. Circulating H19 levels are altered in women with decreased ovarian reserve, establishing H19 as a potential upstream regulator and biomarker of AMH-mediated ovarian function.
Imprinted gene cluster · Upstream AMH regulatorMicroRNAs in Ovarian Reserve
Multiple microRNAs are differentially expressed across low, normal, and high ovarian reserve groups (Saarland University, 2021). Retrieved results propose miRNAs as both biomarkers and therapeutic targets for POI. Exosomal miRNA delivery is described as a novel promising therapeutic strategy for POI by the Warsaw Institute of Mother and Child dataset.
Differential expression · Exosomal deliveryPOI Pipeline: Development Stage Distribution & Clinical Evidence
Visualizing the maturity spread across 10 therapeutic modalities and key clinical trial evidence from the retrieved dataset, analyzed via PatSnap's IP analytics platform.
POI Pipeline: Modalities by Development Stage
Distribution of 10 therapeutic modalities across development stages from approved to discovery, showing the pipeline's early-stage skew.
PRP Intraovarian Trial: AMH Response Rate (n=182)
28% of patients (51/182) showed AMH improvement with a median increase of 167% [95% CI 91–280] at 4 weeks post-treatment (San Diego, 2020).
Geographic Distribution of POI Research Activity
Innovation activity distributed across Chinese, European, North American, and Asia-Pacific institutions — with Baylor College of Medicine as the sole source of oral FSH agonist data.
POI Drug Pipeline: 10 Therapeutic Approaches and Development Status
From approved gonadotropin preparations to discovery-stage noncoding RNA interventions, the POI pipeline spans a broad spectrum tracked by PatSnap's life sciences intelligence and global academic centers.
| Therapeutic Modality | Mechanism / Target | Key Evidence | Stage | Lead Institution |
|---|---|---|---|---|
| Recombinant FSH ± rLH / hMG | FSHR agonism; controlled ovarian stimulation | Meta-analysis; 848-patient real-world study (Torino); comparable pregnancy rates rFSH+rLH vs. hMG | Approved | Aristotle Univ. Thessaloniki; Univ. Torino |
| Hormone Replacement Therapy (HRT) | Estrogen/progesterone replacement; symptom management | First-line treatment for POI; Bayesian network meta-analysis of Chinese patent medicines + HRT (Chengdu University, 2022) | Approved | Multiple; Chengdu Univ. of TCM |
| AMH-Guided FSH Dosing (PIVET Algorithm) | AMH biomarker-directed gonadotropin individualization; target ≤15 oocytes | RCT (North Zealand Hospital, Denmark, 2019): primary endpoint not met; OHSS risk reduction signals observed | RCT Stage | North Zealand Hospital, Denmark; Aarhus University |
| PRP Intraovarian Infusion | Autologous platelet-rich plasma; regenerative biology | Prospective trial n=182; AMH improved in 51/182 (28%); median increase 167% [95% CI 91–280] at 4 weeks | Early Clinical | Office for Reproductive Research, San Diego; AIIMS Mangalagiri |
Track every POI compound from discovery to clinic
PatSnap Eureka monitors patent filings, clinical trial registrations, and literature across 120+ countries in real time.
AMH Biology, FSHR Polymorphisms, and Combinatorial Biomarker Models
The AMH protein requires a C-terminal bioactive domain and an N-terminal pro-domain (110 kDa and 25 kDa fragments respectively) joined non-covalently, with the N-terminal fragment required for receptor-mediated signaling response. This structural complexity has implications for recombinant AMH manufacturing and therapeutic dosing strategies, as confirmed by data from the Argentine Society of Endocrinology and Metabolism.
The Ser680Asn polymorphism in exon 10 of FSHR is specifically identified as modulating ovarian resistance to exogenous FSH, providing a genetic dimension to why some patients require higher gonadotropin doses. Separately, the T allele carrier of AMH rs10407022 was associated with retrieval of more MII oocytes in a Central South University meta-analysis of AMH/AMHR2 polymorphisms.
Composite ovarian reserve models — the AFA (AMH + FSH + Age) and AAFA (AMH + AFC + FSH + Age) models developed at Peking University — improve predictive accuracy over single-marker approaches for guiding gonadotropin dosing. The largest real-world validation dataset in this collection comprised 89,002 IVF cycles across five Chinese academic hospitals (Tongji Hospital/Huazhong University, 2021), providing population-level evidence for ovarian reserve test performance in predicting poor ovarian response. Learn more about how PatSnap's analytics platform supports biomarker landscape mapping for drug development teams.
The World Health Organization has issued an AMH reference preparation (code 16/190), a standardization milestone documented via the University of New South Wales dataset, addressing inter-assay variability that has historically complicated clinical AMH interpretation. NIH-funded research and data from the European Society of Human Reproduction and Embryology continue to shape POI diagnostic criteria and treatment guidelines globally.
Next-Generation Approaches in the POI Pipeline
From recombinant AMH oncofertility co-administration to PTEN pathway modulation, combination and regenerative strategies represent the frontier of POI research identified in the PatSnap Eureka dataset.
Recombinant AMH + Chemotherapy (Oncofertility)
INSERM U1185 and UNSW Sydney independently confirm that co-administration of recombinant AMH during cytotoxic chemotherapy could protect the ovarian reserve by preventing mass activation of primordial follicles. The same UNSW paper notes AMHRII-expressing tumor regression as a secondary indication for recombinant AMH in gynecological malignancies.
Oral Small-Molecule FSHR Agonists (TOP5668, TOP5300)
Baylor College of Medicine is the sole source of small-molecule FSH analog data in the retrieved dataset. TOP5668 and TOP5300 exhibit highly selective FSHR agonism with favorable DMPK and safety profiles in CHO-FSHR cells, proposed as oral single-agent alternatives to injectable recombinant hFSH for ovulation induction and controlled ovarian stimulation.
DHEA Adjuvant + ART Protocols
DHEA supplementation has been explored as an adjuvant to improve ovarian response in diminished ovarian reserve (DOR). A University of Nottingham meta-analysis identified only 3 controlled studies meeting inclusion criteria from 22 publications identified, reflecting the limited evidence base for this combination approach in clinical practice.
PTEN-AKT-FOXO3a Pathway Modulation (Curcumin)
Single-oocyte gene profiling from the Chinese University of Hong Kong identified curcumin as a modulator of the PTEN-AKT-FOXO3a pathway central to primordial follicle dormancy. Long-term curcumin treatment (100 mg/kg) improved AMH, FSH, and estradiol in aging mice and maintained ovarian reserve indicators, positioning this as a candidate natural compound for ovarian reserve protection.
Strongest Clinical Evidence in the POI Dataset
The strongest interventional clinical signal in the dataset is a dual-center randomized controlled trial at North Zealand Hospital, Denmark, comparing AMH-based individualized FSH dosing versus standard dosing in a GnRH antagonist IVF protocol. The primary endpoint — proportion achieving 5–14 oocytes — was not met, though OHSS risk reduction signals were noted. This represents the clearest RCT-level evidence for AMH-guided personalized dosing.
A registered prospective clinical trial of intraovarian PRP in poor-prognosis IVF patients (n=182, San Diego) demonstrated AMH improvement in 28% of patients (51/182), with a median increase of 167% [95% CI 91–280] at a mean of 4 weeks post-treatment. The AIIMS Mangalagiri systematic review concluded PRP reflects "a breakthrough for infertile patients with premature ovarian failure" though without sufficient RCT-level evidence.
DuoStim intraovarian rhFSH (300 IU) during oocyte retrieval to initiate luteal-phase stimulation was evaluated in small cohorts of IOF/DOR patients (n=28/18 per arm) at National Cheng Kung University, Taiwan, supporting feasibility of additional oocyte extraction within the same cycle. A systematic review of 15 articles also documented serial AMH measurement as a monitoring tool for chemotherapy-induced gonadotoxicity. Explore how PatSnap customers use these clinical intelligence signals to guide R&D prioritization.
No data on regulatory submissions, IND-enabling studies, or approved novel POI-specific therapies beyond established HRT and gonadotropin preparations were identified in the retrieved dataset. The oral FSH receptor agonist compounds (TOP5668, TOP5300) from Baylor are at the preclinical stage with no clinical trial data present. For developer access to PatSnap's underlying data infrastructure, see PatSnap Open API.
Premature Ovarian Insufficiency Drug Pipeline — key questions answered
Premature ovarian insufficiency (POI) is defined as loss of ovarian function before the age of 40 years, with a prevalence rate estimated at approximately 1–3% of women. It is accompanied by infertility, reduced life expectancy, increased cardiovascular risk, decreased bone mineral density, and neurological disorders, with current treatment limited to hormone replacement therapy (HRT).
AMH (anti-Müllerian hormone) is secreted by granulosa cells of preantral and small antral follicles and functions as a negative regulator of primordial follicle recruitment and an inhibitor of FSH sensitivity in growing follicles. Serum AMH is recognized as the most sensitive quantitative index of the ovarian follicle pool. Therapeutically, recombinant AMH administered during chemotherapy may protect the ovarian reserve by preventing the mass activation of primordial follicles.
Baylor College of Medicine researchers describe two compounds — TOP5668 and TOP5300 — with favorable pharmacology, drug metabolism, pharmacokinetic, and safety profiles characterized in Chinese hamster ovary (CHO) cells expressing FSHR. These compounds are proposed as single-agent alternatives to injectable recombinant hFSH for ovulation induction and controlled ovarian stimulation. Both are currently at the preclinical stage with no clinical trial data available.
A prospective clinical trial (n=182) from San Diego reported AMH improvement in 51/182 patients (28%) with a median increase of 167% [95% CI 91–280] at a mean of 4 weeks post-treatment. A systematic review at AIIMS India evaluated PRP across eligible study types for POI patients, concluding it reflects a breakthrough for infertile patients with premature ovarian failure, though without sufficient RCT-level evidence. The evidence base remains limited by lack of randomized controlled trial data.
Ab4B19 is an agonistic antibody targeting the BDNF receptor TrkB, developed at Tsinghua University. Intravenous injection of Ab4B19 penetrates ovarian follicles and activates downstream signaling. In both natural aging and cyclophosphamide-induced premature ovarian failure mouse models, Ab4B19 completely reversed the reduction of pre-antral and antral follicles, normalized gonadal hormone levels, and enhanced oocyte quality and fertility. BDNF is downregulated in follicles of POF patients. The compound is currently at the preclinical stage.
AMH-guided dosing algorithms — notably the PIVET rFSH algorithm — personalize gonadotropin dose to reduce OHSS risk while targeting an optimal oocyte yield of 15 or fewer. A randomized controlled trial of AMH-based FSH dosing in a GnRH antagonist protocol found that individualized dosing did not increase the proportion of patients achieving the intended 5–14 oocyte target compared to standard regimen, though OHSS risk signals were observed. AMH-guided dosing is currently at the RCT stage and is not yet standard of care in all settings.
Still have questions? Let PatSnap Eureka search the POI patent and literature landscape for you.
Ask Eureka About POI TherapeuticsAccelerate Your Ovarian Reserve & POI Drug Discovery
Join 18,000+ innovators already using PatSnap Eureka to map therapeutic pipelines, identify white-space opportunities, and monitor competitor activity in reproductive medicine and beyond.
References
- The Role of Noncoding RNA in the Pathophysiology and Treatment of Premature Ovarian Insufficiency — Institute of Mother and Child, Warsaw, 2021
- Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers — Aga Khan University, 2016
- Genetic and clinical predictors of ovarian response in assisted reproductive technology — University of Indonesia, 2017
- AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation — University of Manchester, 2016
- TrkB agonist antibody ameliorates fertility deficits in aged and cyclophosphamide-induced premature ovarian failure model mice — Tsinghua University, 2022
- Single-Oocyte Gene Expression Suggests That Curcumin Can Protect the Ovarian Reserve by Regulating the PTEN-AKT-FOXO3a Pathway — Chinese University of Hong Kong, 2021
- The relationship between H19 and parameters of ovarian reserve — Yale School of Medicine, 2020
- Characterization of micro-RNA in women with different ovarian reserve — Saarland University, 2021
- Recombinant human FSH plus recombinant LH versus r-hFSH alone for ovarian stimulation: systematic review and meta-analysis — Aristotle University of Thessaloniki, 2014
- Controlled Ovarian Stimulation with rFSH+rLH vs. hMG based on number of retrieved oocytes — University of Torino, 2015
- PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation — Aarhus University, 2016
- A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF — North Zealand Hospital, Denmark, 2019
- Discovery and Preclinical Development of Orally Active Small Molecules that Exhibit Highly Selective Follicle Stimulating Hormone Receptor Agonism — Baylor College of Medicine, 2021
- Anti-Müllerian Hormone in Fertility Preservation: Clinical and Therapeutic Applications — INSERM U1185, Université Paris-Sud, 2019
- Translational Physiology of Anti-Müllerian Hormone: Clinical Applications in Female Fertility Preservation and Cancer Treatment — University of New South Wales, 2021
- Regenerative Effect of Intraovarian Injection of Activated Autologous Platelet Rich Plasma — Office for Reproductive Research, San Diego, 2020
- A Systematic Review Evaluating the Efficacy of Intra-Ovarian Infusion of Autologous Platelet-Rich Plasma in Patients With Poor Ovarian Reserve or Ovarian Insufficiency — AIIMS Mangalagiri, 2020
- Evaluation of Ovarian Reserve Tests and Age in the Prediction of Poor Ovarian Response to Controlled Ovarian Stimulation — Tongji Hospital/Huazhong University, 2021
- An Ovarian Reserve Assessment Model Based on Anti-Müllerian Hormone Levels, Follicle-Stimulating Hormone Levels, and Age — Peking University, 2020
- Intraovarian Injection of Recombinant Human Follicle-Stimulating Hormone for Luteal-Phase Ovarian Stimulation during Oocyte Retrieval — National Cheng Kung University, 2022
- Human Mesenchymal Stem Cell Therapy and Other Novel Treatment Approaches for Premature Ovarian Insufficiency — University of Chicago, 2021
- Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis — University of Nottingham, 2013
- Can polymorphisms of AMH/AMHR2 affect ovarian stimulation outcomes? A systematic review and meta-analysis — Central South University, 2020
- Challenges in Measuring AMH in the Clinical Setting — University of New South Wales, 2021
- World Health Organization — AMH Reference Preparation 16/190 and Reproductive Health Standards
- National Institutes of Health — Reproductive Medicine and Ovarian Biology Research
- European Society of Human Reproduction and Embryology — POI Diagnostic Criteria and Clinical Guidelines
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a targeted dataset of patent and literature records and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.